Skip to main content

Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth

When investors review a drug company, pay close attention to its pharma performance, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
  • Author:
  • Publish date:

When investors review a drug company, pay close attention to its pharma performance, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.

Johnson & Johnson's (JNJ)  pharmaceuticals division saw almost 20% revenue growth year-over-year for its most recent quarter to $10.4 billion. 

Shares are down 7% since the start of the year.

Scroll to Continue

TheStreet Recommends

Want exclusive investing insight from Jim Cramer? Get 24/7 access to Jim's charitable trust portfolio with a free trial to Action Alerts PLUS!